C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/02 (2006.01) C07G 99/00 (2009.01) A61K 35/14 (2006.01) A61K 35/16 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) C07K 14/705 (2006.01) G01N 33/543 (2006.01) C07G 17/00 (2006.01)
Patent
CA 2103923
2103923 9213865 PCTABS00014 The invention is concerned with the discovery, isolation and purification of an agent or factor named herein the CR3 modulator or CMF-1 that is synthesized by polymorphonuclear leukocytes (PMN) in response to agonists which enhance CD18 activity. The CR3 modulator binds to CD18 and activates its adhesion-promoting ability. The CR3 modulator appears to be transiently produced by PMN as an acidic amphiphilic lipid. The CR3 modulator can be assayed by adding dilutions of a CR3 modulator-containing solution to resting PMN and observing the ability of CR3 to mediate binding of erythrocytes coated with C3bi (EC3bi). The isolation of the CR3 modulator, its biological and physical properties and diagnostic and therapeutic uses are described.
Hermanowski-Vosatka Anne
Wright Samuel D.
Swabey Ogilvy Renault
The Rockefeller University
LandOfFree
Pmn-derived cr3 modulator and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pmn-derived cr3 modulator and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pmn-derived cr3 modulator and uses thereof will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1606006